- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01772654
Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy
This study will evaluate a type of Magnetic Resonance Imaging (MRI) sequence called arterial spin labeling (ASL). The investigators hope that ASL can better localize areas of the brain (lesions) that cause epilepsy. This type of MRI does not require contrast, does not use any radiation, and adds on 4 minutes to the routine MRI that is done for patients with epilepsy.
The study hypothesis is that in patients with refractory epilepsy, Arterial Spin Labeling (ASL) MRI will show areas of abnormality in the brain to the same degree as single-photon emission computerized tomography (SPECT) and positron emission tomography (PET) studies.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Currently, in presurgical evaluation of epilepsy patients, PET and SPECT studies are utilized to evaluate metabolic and perfusion abnormalities respectively to localize seizure onset. This is especially true in "MRI negative" patients, whose lesion is not visible on standard MRI techniques. PET and SPECT studies have numerous disadvantages, including radiation exposure, injection of contrast or isotopes, cost, and are often difficult to access for many patients.
Arterial spin labeling (ASL) MRI sequences show perfusion related abnormalities without using contrast, in a relatively short amount of time, and can be done during a normal MRI for evaluation of epilepsy. This is of interest because if there is a good correlation, ASL MRI sequences could be used in addition, or in place of, these other studies that require injection of isotopes and radiation from CT scans.
ASL sequences have been shown to localize certain epileptogenic abnormalities such as tubers in tuberous sclerosis. A previous study demonstrated ASL changes inter- and post-ictally in one patient without other MRI changes. This is a promising technique that has not been fully evaluated as of yet. Of note, all studies done in this area in regards to epilepsy have been retrospective, small studies. The investigators plan to perform a study that is prospective, with a comparatively large sample of patients.
Study Design: Consultants in the epilepsy clinic will identify potential subjects on the patients' initial evaluation. Just after the consultation is finished, in the epilepsy clinic, the study will be described to the patient along with risks and benefits, and informed consent will be obtained by one of the researchers or research personnel in the clinic. If the patient agrees with the study, the MRI department will be notified of the patient's participation. At that time, the patient's already scheduled MRI will have the addition of ASL sequences. This will add approximately 4 minutes to the MRI. The patient will then have other imaging investigations as deemed necessary by the treating consultant. This may include PET and SPECT. If the patient is admitted to the EMU, ictal and interictal SPECT are likely to be done. After the patient has had the full evaluation, we will compare the ASL MRI sequences to the basic MRI, and PET and SPECT if performed.
We will also use software already developed to determine the quantitative blood flow to the abnormalities found on the ASL sequences.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Medically refractory partial epilepsy.
- Over the age of 18 years.
- Scheduled to have routine epilepsy-protocol MRI after initial evaluation in neurology clinic at Mayo Clinic, Rochester.
- Anticipated to undergo epilepsy monitoring unit (EMU) monitoring.
Exclusion Criteria:
- Patients with a generalized epilepsy.
- Under the age of 18 years.
- Unable to undergo MRI imaging of the brain.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Left Temporal Lobe Epilepsy Subjects
Arterial Spin Labeled (ASL) MRI sequence
|
The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood. This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence. |
|
Active Comparator: Control Subjects
Arterial Spin Labeled (ASL) MRI sequence
|
The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood. This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intensity of the MRI Signal in the Left Temporal Precentral Zone
Time Frame: Approximately in the middle of the MRI procedure
|
Subjects who were already scheduled to have a Magnetic Resonance Imaging (MRI) procedure as part of an evaluation for epilepsy had an additional sequence added during the MRI.
The additional MRI sequence was called Arterial Spin Labeling (ASL), and consisted of 4 minutes additional time in the MRI scanner.
The ASL sequence did not use any contrast or radiation.
The ASL sequence is a blood flow measure, and compared the intensity of the MRI signal in patients with left temporal lobe epilepsy to the intensity of the MRI signal in patients with normal brains.
Intensity of MRI signal is measured on the MRI image slices in different anatomic regions as an optical density (dark to bright).
It is then referenced to a region of the brain that is considered stable standard as a ratio.
|
Approximately in the middle of the MRI procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cheolsu Shin, MD, Mayo Clinic
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-006882
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Focal Epilepsy
-
Assistance Publique - Hôpitaux de ParisMedtronicRecruitingEpilepsy | Focal Epilepsy | Drug Resistant | Drug-resistant Focal Epilepsy | Epilepsies, FocalFrance
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
Peking Union Medical College HospitalGuidon Pharmaceutics Ltd.RecruitingRefractory Focal EpilepsyChina
-
Rapport Therapeutics Inc.RecruitingEpilepsy | Focal Epilepsy | Focal Onset Seizure | Seizure | Refractory Focal Epilepsy | Focal SeizureUnited States
-
Neuroelectrics CorporationCompletedEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Fondation Ophtalmologique Adolphe de RothschildRecruitingDrug Resistant Epilepsy | Pediatrics | Epilepsies, FocalFrance
-
BiocodexCompletedPharmacoresistant Focal EpilepsiesFrance
-
UCB Biopharma S.P.R.L.PRA Health SciencesCompletedHighly Drug-resistant Focal EpilepsyBelgium, Bulgaria, Germany, Hungary, Netherlands, Spain
-
UCB Biopharma SRLTerminatedAn Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal EpilepsyHighly Drug-resistant Focal EpilepsyBelgium, Bulgaria, Germany, Hungary, Netherlands, Spain
-
Azienda Ospedaliero-Universitaria di ModenaOspedale Pediatrico Bambino Gesù, Rome (IT); Azienda Sanitaria Universitaria... and other collaboratorsRecruitingEpileptic Encephalopathy | Epilepsies, Focal | EpilepsiesItaly
Clinical Trials on Arterial Spin Labeled (ASL) MRI sequence
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
University of Texas Southwestern Medical CenterNational Cancer Institute (NCI)Completed
-
University of NottinghamNot yet recruitingKidney Diseases | Ultrasonography | Kidney Injury, Acute | Perfusion ImagingUnited Kingdom
-
Jonsson Comprehensive Cancer CenterTerminatedMalignant Brain NeoplasmUnited States
-
Asan Medical CenterRecruitingBrain Metastases | RadiosurgeryKorea, Republic of
-
Beth Israel Deaconess Medical CenterNovartis; Pfizer; Dana-Farber Cancer Institute; Brigham and Women's HospitalCompletedRenal Cell CarcinomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyCompletedStage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell CancerUnited States
-
University Hospital, BordeauxCompletedNeonatal Hypoxic Ischemic EncephalopathyFrance
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer Institute; AmgenTerminatedRenal Cell CarcinomaUnited States
-
Beijing Friendship HospitalUnknownOcular Ischemia SyndromeChina